Monoclonal antibodies produced against chondroitinase-treated human adult cartilage proteoglycans were selected for their ability to recognize epitopes on native proteoglycans. Binding analyses revealed that four of these monoclonal antibodies each recognized a different epitope on the same proteoglycan molecule which represents a subpopulation of a high buoyant density (D 1) fraction of human articular cartilage proteoglycans (10, 30, 50 and 60% in fetal-newborn, 1.5 years old, 15 years old and 52-56 years old cartilages, respectively). Analysis of epitope specificities revealed that BCD-7 and EFG-4 monoclonal antibodies recognized epitopes on proteoglycan monomer which are associated with the protein structure in that they are sensitive to cleavage by Pronase, papain and alkali treatment and do not include keratan sulphate, chondroitin sulphate or oligosaccharides. The BCD-4 and KPC-190 epitopes also proved to be sensitive to Pronase or papain digestion or to alkali treatment, but keratanase or endo-,8-galactosidase also reduced the immunoreactivity of these epitopes. These observations indicate that the BCD-4 and KPC-190 epitopes represent peptides substituted with keratan sulphate or keratan sulphate-like structures. The BCD-4 epitope is, however, absent from a keratan sulphate-rich fragment of human adult proteoglycan, while the other three epitopes were detected in this fragment. None of these four epitopes were detected in the link proteins of human cartilage, in the hyaluronic acid-binding region of human newborn cartilage proteoglycan, in Swarm rat chondrosarcoma proteoglycan, in chicken limb bud proteoglycan monomer and in the small dermatan sulphate-proteoglycan of bovine costal cartilage. EFG-4 and KPC-190 epitopes were not detected in human fetal cartilage proteoglycans, although fetal molecules contained trace amounts of epitopes reactive with BCD-4 and BCD-7 antibodies.
INTRODUCTION
The basic structural unit of the cartilage proteoglycan monomer consists of a central protein core to which glycosaminoglycansand N-and O-linked oligosaccharides are covalently attached Hascall & Kimura, 1982) . A specialized region of the proteoglycan core protein, the hyaluronic acid binding region, which is present at one end of the molecule (Buckwalter et al., 1982) specifically binds to hyaluronic acid to form macromolecular aggregates (Hardingham & Muir, 1972; Hascall & Heinegard, 1974) . The glycosaminoglycan attachment region contains both chondroitin sulphate and keratan sulphate. In bovine nasal cartilage, the chondroitin sulphate-rich region of the proteoglycan monomer, remote from the hyaluronic acid-binding region, contains a large number of chondroitin sulphate chains interspersed with relatively less keratan sulphate chains (Heinegard & Axelsson, 1977) . The core protein, between the hyaluronic acid-binding region and the chondroitin sulphate-rich region, involves a short polypeptide region containing predominantly keratan sulphate chains, and called the keratan sulphate-rich region of the molecule (Heinegard & Axelsson, 1977) .
Biochemical studies of the structure of proteoglycans were greatly facilitated by the introduction of improved purification techniques (Hascall & Sajdera, 1969) which permitted the production of polyclonal antisera to purified proteoglycans and their substructures (Keiser & DeVito, 1974; Wieslander & Heinegard, 1979; Poole et al., 1980a; Kimura et al., 1981; Glant & Levai, 1983; Pacifici et al., 1983; Ratcliffe et al., 1984) . The failure to produce a detectable immune response against isolated chondroitin sulphate and keratan sulphate chains (Boake & Muir, 1955; Loewi & Muir, 1965; Sandson et al., 1966) led to the speculation that the glycosaminoglycans of proteoglycans are non-antigenic. Removing the chondroitin sulphate chains either with testicular hyaluronidase or with chondroitinase ABC could, however, enhance the immunoreactivity of proteoglycans and these treatments often revealed 'new' antigenic sites which suggested that the antigenic determinants are closely associated with the protein core (Buckwalter et al., 1982; Wieslander & Heinegard, 1979; Poole et al., 1980a, b; Glant & Levai, 1983) . It was then discovered that polyclonal antibodies to the unsaturated oligosaccharides of chondroitin sulphate could be produced by immunization with heterologous proteoglycans treated with chondroitinase AC or ABC (Christner et al., 1980) . Rabbit autoantibodies Vol. 234 Abbreviation used: e.l.i.s.a., enzyme-linked immunosorbent assay.
to degraded glycosaminoglycans, including hyaluronic acid, also occur naturally in preimmune animals .
Introduction of monoclonal antibody technology (Kohler & Milstein, 1975) , with antibodies which can recognize single epitopes (antigenic determinants), has opened a new perspective both for the immunology of proteoglycans and for the study of proteoglycan structure. Monoclonal antibodies have been produced that can recognize saturated and unsaturated oligosaccharides of chondroitin sulphate (Caterson et al., 1981; Jenkis et al., 1981; Couchman et al., 1984) and intact keratan sulphate (Caterson et al., 1983; Fudenburgh et al., 1983) . There are also some reports of monoclonal antibodies which react with determinants associated with the proteoglycan core protein: two reports of antibodies to the hyaluronic acid-binding region (Caterson et al., 1982; Stevens et al., 1985) and another paper about the partial characterization of an antibody (Dorfman et al., 1980) which reacts with the core protein of proteoglycan translated from mRNA by a cell-free protein-synthesizing system (Upholt et al., 1979 (Heinegard, 1972) were prepared as previously described (Tang et al., 1979; Glant & Levai, 1983) . Proteoglycans isolated from combined samples of eight human articular cartilages (age range, 52-56 years) were used both for immunization and as test materials in present experiment.
Cartilage slices and tissue homogenate of rat chondrosarcoma were extracted with 4 M-guanidinium chloride containing enzyme inhibitors (Roughley & White, 1980) . Proteoglycan aggregate, fraction Al, was prepared by density gradient centrifugation under associative conditions in the presence of CsCl (Hascall & Sajdera, 1969) . Aggregate was dissociated with 4 M-guanidinium chloride and recentrifuged in 4 M-guanidinium chloride to purify link protein from fractions AID5-AID6 (Tang et al., 1979) and proteoglycan monomers of high buoyant density from fraction AIDI (Glant, 1982a) . High buoyant density proteoglycan monomers (fraction Dl) were also obtained from 4M-guanidinium chloride extract of cartilage by using dissociative density gradient centrifugation in 4 M-guanidinium chloride/3 M-CsCl for 60 h at 100000g. Keratan sulphate-enriched fragments of proteoglycan core protein These were prepared from bovine nasal cartilage (pooled AlDI and A1D2 fractions of two 4-year-old steers) and human articular cartilage (pooled A1D2 fractions of three 66-year-old individuals) proteoglycans by the method described by Heinegard & Axelsson (1977) . Bovine nasal cartilage proteoglycan (50 mg) and humanproteoglycan (40 mg)digested withchondroitinase ABC were used for trypsin digestion prior to separation on Sepharose CL-6B. Keratan sulphate-containing fragments were recovered in the first peak of bovine nasal and in the second peak of human articular cartilage proteoglycans, which later were rechromatographed on DEAE-cellulose. They represented 0.9% and 2.3% ofthe total glucosamine content of bovine and humam proteoglycan monomer, respectively. The glucosamine/ galactosamine ratios were 9.19 and 5.71 in the keratan sulphate-enriched fragments of proteoglycans of bovine and human cartilage, respectively: they did not contain detectable amounts of uronic acid. The protein/glucosamine ratios were 5 for bovine and 2 for human, increasing to 12 and 10.8 after keratanase digestion, respectively. Hyaluronic acid-binding region This was a generous gift from Dr. P. J. Roughley, Joint Diseases Laboratory. It was prepared from newborn human proteoglycan aggregate by using clostripain digestion .
Other proteoglycans and link protein Keratan sulphate proteoglycan was isolated from bovine corneas and purified by DEAE-cellulose chromatography, both before and after chondroitinase ABC digestion (Nakazawa et al., 1983) . Keratan sulphate proteoglycans were eluted from concanavalin A-Sepharose with 1 M-ac-methyl D-mannoside dissolved in 50 mMTris/HCl, pH 7.0, containing 1 M-NaCl. The concanavalin A-bound fraction did not contain any detectable galactosamine and the protein/glucosamine ratio was 8.25. Dermatan sulphate proteoglycan (DS-PG-II) of bovine articular cartilage and human articular cartilage link protein were generously supplied by Dr. L. C. Rosenberg (Rosenberg et al., 1985) and Dr. P. J. Roughley respectively, having been prepared as described by these authors.
Digestions of proteoglycan
Chondroitinase ABC was used as 0.1 unit/mg of proteoglycan in 0.1 M-sodium acetate/Tris/HCl buffer, pH 7.3 (Hascall & Heinegard, 1974) containing 1 mmiodoacetamide, 1 mM-phenylmethanesulphonyl fluoride, S mM-EDTA and 5g of pepstatin/ml to inhibit cysteine, serine, metallo-and aspartate-proteinases, respectively. Keratanase was used at 0.1 unit/mg of proteoglycan in 50 mM-Tris/HCl, pH 7.2, containing 80 mM-NaCl with the proteinase inhibitors listed above (Conrad et al., 1982) . Testicular hyaluronidase (at 10 ,ug or 240 turbidity units/mg of proteoglycan) was used in 0.1 M-sodium acetate buffer, pH 5.0, containing 0.15 M-NaCl, 0.05 M-Na2SO4 and the above proteinase inhibitors (Glant, 1982b) . Neuraminidase at 0.2 unit/mg of proteoglycan and sulphatases at 1 unit/mg of proteoglycan were used in 0.15 M-sodium acetate buffer, pH 5.1, containing 0.25 M-NaCl, 10 mM-CaCl2 and proteinase inhibitors (Friedler, 1976) . Endo-,/-galactosaidase (0.05 unit/mg of proteoglycan) in 0.1 M-sodium acetate, pH 5.8 (Fukunda & Matsumura, 1975) and endo-/,-N-acetylglycosaminidase H (0.05 unit/mg of proteoglycan) in 0.1 M-citrate/phosphate buffer, pH 5.3 (Hughes & Jeanloz, 1964) were used with proteinase inhibitors listed above. Effects ofglycosidic enzymes were determined by analytical methods and the protein/hexosamine ratio was expressed (e.g. Table 5 ). Alkaline phosphatase (1 unit/mg of proteoglycan) was used in 1 M-diethanolamine/HCl buffer, pH 9.8, containing 0.5 mM-MgCl2. Tosylphenylalanine chloromethanetreated trypsin at 27.5 ,ug or 6.5 units/mg ofproteoglycan, tosyl-lysine chloromethane-treated chymotrypsin (100 ,ag or 4.5 units/mg of proteoglycan) and Pronase (5 ,ug/mg ofproteoglycan) were in 50 mM-Tris/HCl, pH 7.5 (Keiser & DeVito, 1974) . Pepsin (5 #sg/mg of proteoglycan) in 0.2 M-sodium acetate, pH 5.0, and papain (10 ,ug/mg of proteoglycan) 'were in 0.2 M-sodium acetate, pH 5.0, containing 5 mM-EDTA and 5 mM-cysteine (Roughley & White, 1980) . After incubation, proteinase contaminants in glycosidases were inhibited with fresh proteinase inhibitors described above and the enzymes were inactivated by 3 min of boiling ( This was used to release 0-linked oligosaccharides and 0-linked glycosaminoglycans (Carlson, 1968) from the core protein of human articular and bovine nasal proteoglycans. Proteoglycan monomer (2-10 mg) was dissolved in 800 1d of 50 mM-NaOH and 1 M-sodium borohydride and incubated for 48 h at 45°C. The solution was then neutralized by addition of glacial acetic acid and 0.1 M-sodium acetate, pH 6.0, to a final volume of 2 ml. Hydrolysis of proteoglycan monomers were also performed with 50 mm-, 0.1 M-, 0.25 M-and 0.5 M-NaOH as indicated. NaOH was neutralized with HCl and the volume adjusted to 2 ml with 0.1 M-sodium acetate, pH 6.0.
Reduction and alkylation
Reduction of cysteine and a subsequent alkylation was performed by Heinegard's (1977) method. Proteoglycan monomer (Dl) (2 mg) was dissolved in 50 mM-Tris/HCl, pH 7.35, containing 4 M-guanidinium chloride and 5 mM-dithiothreitol. The mixture was incubated at 40°C for 4 h. lodoacetic acid was added to a concentration of 15 mm and the mixture was incubated at 25°C for a further 20 h. Sample was dialysed against potassium acetate and then exhaustively against water. Column chromatography Proteoglycan monomer (Dl fraction) (2 mg) was dissolved in 1.0 ml of 0.2 M-sodium acetate, pH 5.5, and chromatographed on Sepharose CL-2B or CL-6B (1 cm x 120 cm) bydownward elution at6 ml/h, collecting 2 ml fractions. Fragments of 2-10 mg of proteoglycan monomer in 2 ml produced by alkaline or enzymic digestion were prepared on Sephacryl S-200 superfine (1 cm x 120 cm) equilibrated with 0.5 M-sodium acetate, pH 5.5, as described above.
Analytical methods
Uronic acid was determined by the carbazole reaction (Bitter & Muir, 1962) and sialic acid by the periodate/ resorcinol method (Jourdian et al., 1971) . Samples for hexosamine analysis were hydrolysed in sealed tubes under N2 in 4 M-HCI at 100°C for 8 h (Roughley & White, 1980) . The hydrolysates were dried under vacuum and redissolved on 0.2 M-citrate buffer, pH 3.2. Samples were analysed with a Durrum amino acid analyser, using a single-buffer system (0.2 M-citrate, pH 5.25, for hexosamines and 0.2 M-citrate/0. 1 M-borate, pH 5.28, for ga-lactosaminitol) and hexosamine and galactosaminitol contents were determined by comparison with standards. Protein content was estimated by Lowry's method using bovine serum albumin as standard (Lowry et al., 1951) .
Mon Ia antibodies
Female BALB/c mice (4-6 weeks) were immunized intraperitoneally with 150 jug of AIDI fraction of human articular proteoglycans digested with chondroitinase ABC in 150 pl of Freund's complete adjuvant. Mice were reinjected (two to four times total) on every third week with chondroitinase-ABC digested human proteoglycans until the blood samples (obtained from the retrobulbar venous plexus) gave positive titre at 1:1000-1:10000 serum dilution using the e.l.i.s.a. described below. Mice were given an intravenous injection of 100 jug of chondroitinase ABC-digested human articular proteoglycans 3 days before killing. Spleens were removed and the cells were fused with Sp2/O-Agl4 murine myeloma cells by using poly(ethylene glycol) (Kohler & Milstein, 1975; Oi & Herzenberg, 1980; Zola & Brooks, 1982; Glant et al., 1985) . Hybridomas were selected in HATmedium (hypoxanthine-, aminopterin-and thymidinecontaining RPMI 1640 medium with 15% fetal calf serum). Antibody production of hybridomas was screened using native (non-digested) AlDI fraction of human adult articular cartilage for the coating of 96-well microtitration plates (Nunclon; Immunoplate I, F). Positive cell lines were cloned by limiting dilution in hypoxanthine-, thymidine-containing medium in the presence of syngeneic peritoneal macrophages (Fazekas de St. Groth & Scheidegger, 1980) . Cloned hybridoma cells were injected intraperitoneally into BALB/c mice to produce ascites fluids. Monoclonal antibodies were purified on Sepharose 4B and AcA44 columns followed by binding a staphyloccoccal protein A (Watanabe et al., 1981) .
Affinity chromatography
Sepharose CL-4B was activated with CNBr (March et al., 1974) and antibodies were bound (2.4-2.6 mg/ml of wet gel) as described elsewhere (Glant, 1982a) . Unlabelled proteoglycan monomer as carrier (2 mg) and/or 2.6 x 106 c.p.m. of 1251-labelled proteoglycan monomer Dl were loaded on each column (1.4 cm x 7.0 cm) and recirculated overnight at room temperature. Unbound proteoglycans were removed by exhaustive washing with radioimmunoassay buffer (see below), and the bound fraction was eluted with 3 M-potassium thiocyanate in phosphate-buffered saline containing azide. Unbound and bound fractions of proteoglycan monomers were used for inhibition assays. By this procedure, about 90% of radiolabelled antigens was recovered.
Enzyme-linked immunosorbent assay
Supernatants of hybridomas, immunoglobulin classand subclass-specificity of monoclonal antibodies, specificity of monoclonal antibodies to variable epitopes and the cross-reactivity of monoclonal antibodies to proteoglycans obtained from other species were determined by e.l.i.s.a. as described previously (Poole et al., 1984; Glant et al., 1977 Glant et al., , 1985 . Mouse immunoglobulin class-and subclass-specificity of antibodies were determined by heavy-and light-chain-specific rabbit anti-mouse immunoglobulins (Miles Laboratories).
Three monoclonal antibodies (BCD-4, BCD-7 and EFG-4) were identified as IgGI and the KPC-190 as IgG2a. All the four monoclonal antibodies used in this experiment contained K-light chains. Radioimmunoassay Proteoglycan monomers were labelled with 1251I by using chloramine-T (Sonada & Schlamowitz, 1970) . Direct and competitive binding radioimmunoassays were used. The conditions were as described recently (Caterson et al., 1983) . Radioimmunoassay (RIA) buffer at pH 8.1 was used to facilitate the binding of monoclonal antibodies to protein A of Staphylococcus aureus. Binding curves were determined as follows. Monoclonal antibodies were serially diluted, and 100 l1 of each dilution was incubated with 50,1 of 1251-proteoglycan for 2 h at 37°C. A 10% (w/v) suspension of protein A-bearing Staphylococcus aureus (Zysorbin) (25 1l) was added and the mixture was incubated for 30 min at 37 'C. Pellets were washed twice with radioimmunoassay buffer. Radioactivity was determined with an LKB gamma counter (model 1270, Rackgamma II) and the percentage of the total proteoglycan bound was recorded.
For competitive binding (inhibition) radioimmunoassay, monoclonal antibodies were diluted so that they would precipitate 40-50% of the total radiolabelled proteoglycan. Unlabelled proteoglycan solutions (standards, unknown samples, column fractions and proteoglycan enzyme/alkali digests) in 50,l of radioimmunoassay buffer were mixed with 100 ,ul of antibody dilution and incubated overnight at 37 'C. 1251-proteoglycan (50 ,dl) was then added, incubated for 2 h at 37 'C and the assay carried out as described for the bind- 
RESULTS

Monoclonality of antibodies
Four hybridomas producing monoclonal antibodies (BDC-4, BCD-7, EFG-4 and KPC-190) against native proteoglycan monomers were selected from more than 100 antibody-producing cell lines raised to chondriotinase ABC-digested proteoglycans of human ad,ult cartilage. In competitive e.l.i.s.a. binding assays us$ng peroxidaselabelled and unlabelled antibodies, none of these four monoclonal antibodies inhibited the binding of the three others to proteoglycan antigens, indicating that they recognize different epitopes on these proteoglycan molecules (Fig. 1) .
Proteoglycan monomer (D l fraction) of human cartilages was separated into two subpopulations (bound and unbound) by any of these four monoclonal antibodies by using an immunosorbent procedure (Table  1) . The antibody-bound subpopulation of proteoglycans reacts completely with the other three monoclonal (a) antibodies, which means that BCD-4, BCD-7, EFG-4
and Effects of alkali and sodium borohydride on epitopes -log2 (Dilution of unlabelled antibodies)
Binding of monoclonal antibodies to epitopes could be Monoclonal antibodies BCD4 (a), BCD-7 (b) and EFG4 Two-fold dilution (50 ,1 volumes) of unlabelled antibodies (c) were labelled with horseradish peroxidase and used with (starting at 20 mg/ml) were added and incubated with 50 ,ul unlabelled monoclonal antibodies [BCD-4 (0), of peroxidase-labelled BCD-4 (2 ,ug/ml), BCD-7 (A) EFG-4 (U) and KPC-190 (0)] in competitive e.l.i.s.a.
(2.1 jug/ml) and EFG-4(1.8 ,ug/ml)monoclonal antibodies, Microplateswerecoatedwithnativeproteoglycanmonomer respectively. Table 5 . Sulphatases, alkaline phosphatase and neuraminidase alone had no effect on antibody binding. Complete immunoinhibition profiles for BCD-4 are shown in Fig. 3 where details of the effects of chondroitinase ABC, keratanase, mixed glycosidases and endo-,B-galactosidase are given.
Effect of proteolytic cleavage Pronase and papain digestions essentially abolished the binding of 200 ng proteoglycan monomer to all four monoclonal antibodies (Table 5) . A full immunoinhibition curve for BCD-4 is shown in Fig. 3 . Pepsin, chymotrypsin and trypsin reduced reactivity to a lesser degree. In each case the epitope recognized by BCD-4 was more susceptible to proteinase treatments. Column fractions ofpepsin, chymotrypsin and trypsin-treated proteoglycan monomer, however, showed a broad range of inhibition from the void ( (Table 5 and Fig. 3 ). All the other three monoclonal antibodies reacted with the keratan sulphate-rich fragment of human adult cartilage, but much more protein was required to produce similar inhibition compared with native cartilage proteoglycan (Table 6 ). Full immunoinhibition curves for BCD-4, are shown in Fig. 4 . Keratanase treatment significantly reduced the immunoreactivity of the KPC-190 epitope located in this fragment (Table 6) . A mild alkaline treatment slightly reduced the inhibitory effect of this fragment on the binding of EFG-4 and BCD-7 monoclonal antibodies and abolished it on the binding of KPC-190 antibody (Table 6 ). Pronase digestion of the keratan sulphate-rich fragment destroyed the immunoreactivity to all the antibodies (Table 6 ).
DISCUSSION
Monoclonal antibodies characterized in this paper react with different epitopes of the same native adult human proteoglycan monomer which are all sensitive to enzymic and non-enzymic degradation. Column profiles of cleaved proteoglycan monomers suggested that the antigenic determinants reside in a polypeptide region of minimum Mr 30000-40000 (results not shown).
Epitopes revealed by BCD-7 and EFG-4 monoclonal antibodies proved to be sensitive to proteinase digestions and alkaline cleavages yet resistant to all the glycosidases, sulphatases and phosphatases studied, suggesting that these epitopes of proteoglycan molecule are highly associated with the protein structure and do not include . This inhibition was seen at relatively high concentrations: inhibition required 100-150-fold more keratan sulphate (on the basis of dry weight) than native cartilage proteoglycan monomer. Also KPC-190 reacted much more strongly with corneal keratan sulphate proteoglycan and with keratan sulphate-rich fragments of human adult proteoglycan monomer. Together these results indicate that the KPC-190 epitope has an obligate requirement for protein core for recognition of keratan sulphate by antibodies. Also the keratan sulphate binding would appear to be weaker than that observed for BCD-4. BCD-4 and KPC-190 are clearly present in different parts of the molecule, in view of the analysis of fragments isolated from adult monomer. The production of antibodies to keratan sulphate is presumably selected to the absence of this molecule from mice (Venn & Mason, 1985) .
Since both the hyaluronic acid-binding region and the keratan sulphate-enriched fragment of human cartilage proteoglycan proved to be free of BCD-4 epitope, we believe that this epitope is located only in the chondroitin sulphate-rich part ofthe core protein. The BCD-7, EFG-4 and KPC-190 epitopes were detected both in keratan sulphate-and chondroitin sulphate-bearing fragments of the core protein of proteoglycan monomer. The putative locations of all four epitopes are shown diagrammatically in Fig. 5 .
This study also presents some new information on the heterogeneity of human proteoglycans. The monoclonal antibodies BCD-4, BCD-7, EFG-4 and KPC-190 recognized protein related epitopes on the same proteoglycan molecule, but this was only a subpopulation in the Dl fraction of human adult articular cartilage proteoglycans. Thus, there may exist in cartilage different molecular species with genetically distinct core proteins Vol. 234 protein ofproteoglycan monomer ofhuman adult cartilage BCD-7 and EFG-4 epitopes (peptides) are present in both keratan sulphate-and chondroitin sulphate-attachment region. BCD-4 epitope (protein associated with a keratanase-sensitive component) is located only in the chondroitin sulphate-attachment region. KPC-190 epitope (protein associated with keratan sulphate) was found mainly in the keratan sulphate-rich fragment of proteoglycan monomer, but it is also present in chondroitin sulphate-attachment region of the molecule. (Hopwood & Robinson, 1975; Stanescu et al., 1977; Roughley & White, 1980; Heinegard et al., 1981; Champion et al., 1982; Stanescu & Stanescu, 1983) . The absence of these epitopes in fetal proteoglycans also suggests the absence of distinct proteoglycan subpopulations in fetal cartilage containing these epitopes. After birth all four epitopes appear in human articular cartilage and increase in amount with age, indicating the appearance of distinct proteoglycan molecules characteristic of more mature chondrocytic expression, as suggested earlier (Champion et al., 1982) . Their presence in proteoglycans of some other cartilages of different species indicate that these antigenic determinants are associated with structural features which are partly conserved during phylogenesis rather than during ontogenetic development (Glant et al., 1975) . Further analysis of proteoglycans isolated by monoclonal antibodies can probably help to understand the structural organization of proteoglycans during cartilage development and the biosynthetic abnormalities in arthritic cartilage.
